Quarterly report [Sections 13 or 15(d)]

Summary of Significant Accounting Policies (Tables)

v3.25.1
Summary of Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2025
Summary of Significant Accounting Policies  
Schedule of significant expense categories

    

Three Months Ended

March 31, 

March 31, 

    

2025

    

2024

Operating expenses:

Clinical

$

1,817,232

$

2,274

Chemical, manufacturing and controls

135,122

42,637

Research and preclinical

24,134

63,716

Regulatory

21,658

(16)

Other research and development costs

438,852

235,106

Total research and development

2,436,998

343,717

General and administrative expenses

1,992,928

970,384

Total operating expenses

$

4,429,926

$

1,314,101

Loss on debt conversion with related party

6,134,120

Interest expense (income), net

147,090

(22,766)

Exchange loss, net

 

23,274

 

Net loss before income taxes

$

10,734,410

$

1,291,335